Acumen and Lonza to produce Alzheimer’s drug sabirnetug
Acumen has entered a partnership with Lonza to further the development of sabirnetug, a potential treatment for Alzheimer's disease.
Acumen has entered a partnership with Lonza to further the development of sabirnetug, a potential treatment for Alzheimer's disease.
What's Your Reaction?
